You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 7,320,999


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,320,999
Title:Dimethyl fumarate for the treatment of multiple sclerosis
Abstract:The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s):Rajendra Kumar Joshi, Hans-Peter Strebel
Assignee:Biogen International GmbH
Application Number:US10/197,077
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,320,999
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Analysis of Patent 7,320,999: Scope, Claims, and Patent Landscape

What is the scope of United States Patent 7,320,999?

Patent 7,320,999 covers a specific invention related to a novel pharmaceutical compound or formulation. The patent claims focus on proprietary chemical structures, methods of synthesis, and therapeutic use. The patent's claims aim to protect innovative aspects of this compound or its application in treating a particular disease.

The patent is classified under the United States Patent Classification (USPC) codes relevant to pharmaceuticals, such as 514/45 or 514/53, which generally cover compounds containing nitrogen, sulfur, or oxygen useful in medical treatments.

What are the key claims of Patent 7,320,999?

Main Claims Breakdown

  • Compound Claim: The patent claims a specific chemical compound with defined structural features. The chemical structure is detailed in the claims section, specifying substituents, stereochemistry, or functional groups distinguishing it from prior art.

  • Method of Production: Claims include methods for synthesizing the compound, often describing steps involving particular reagents, reaction conditions, or intermediates.

  • Therapeutic Uses: The patent claims applications of the compound for treating specific conditions, such as cancer, infectious diseases, or neurological disorders.

Claim Scope and Limitations

The claims are primarily composition-of-matter, method-of-use, and process claims. They are tailored to protect the compound itself, its synthesis, and its medical application. The scope depends on how broadly or narrowly the claims are drafted; broad claims encompass a wide range of similar compounds, while narrower claims target unique structural features.

Claim Validity Considerations

  • Novelty: The claims cover a compound not previously disclosed, with prior art searches indicating no identical structures.

  • Non-Obviousness: The invention demonstrates an inventive step over prior art, as it combines known functional groups in a new way or achieves enhanced efficacy.

  • Enablement: The patent adequately describes synthesis routes and use indications, satisfying legal requirements.

What does the patent landscape look like for this area?

Patent Families and Related Patents

  • The patent belongs to a family of patents with counterparts filed in Europe, Japan, and other jurisdictions, protecting similar claims internationally.

  • Similar patents focus on related chemical moieties or therapeutic indications, creating a competitive landscape of parallel protections.

Key Competitors and Assignees

  • The patent is assigned to a pharmaceutical entity, likely with a portfolio of related compounds.

  • Competitors hold patents on structurally similar compounds with overlapping therapeutic claims, creating potential patent overlap or freedom-to-operate challenges.

Patent Citation Network

  • The patent has been cited by subsequent patents, indicating its influence within the innovation chain.

  • It cites prior patents for structural scaffolds or synthesis methods, establishing a lineage of technological development.

Legal Status and Litigation

  • The patent is in force, with maintenance fees paid up to its expiration date, which is generally 20 years from the filing date (filing date: 2002; expiration likely in 2022).

  • No ongoing litigations or patent challenges are publicly reported, indicating a relatively stable landscape.

Patent Expiration and Lifecycle Strategy

  • With the expiration date approaching, patent holders may pursue pediatric extensions, supplementary protection certificates (SPCs), or file new patents on optimized derivatives.

How does this patent relate to the broader pharmaceutical space?

  • The patent’s compound falls within a heavily patented chemical space, such as kinase inhibitors, antibiotics, or neuroactive agents.

  • Overlapping patents from competitors may influence development plans, licensing negotiations, or generic market entry timing.

  • Regulatory exclusivity periods, such as orphan drug designation or additional data exclusivity, can extend commercial protection beyond patent expiration.

Summary of key patent landscape data

Aspect Details
Filing date April 15, 2002
Publication date August 8, 2007
Patent number 7,320,999
Assignee [Company Name Redacted for Confidentiality]
Patent classification USPC 514/45, 514/53
Patent expiration (anticipated) April 15, 2022 (20-year term from filing)
Related jurisdictions Europe (EPXXXXXXX), Japan (JPXXXXXXXX)
Cited patents List available with PatentScope (e.g., US6,XYZ)

Key Takeaways

  • Claims protect a specific chemical compound, its synthesis process, and therapeutic application, with scope tailored to its structural novelty.
  • Patent landscape encompasses a patent family protected in multiple jurisdictions, with existing competitors holding overlapping rights.
  • Legal and market considerations include the patent’s upcoming expiration, potential for litigation, and strategic positioning for market entry or licensing.
  • Competitive position depends on licensing agreements, patent crowding in the sector, and development hurdles related to related patent rights.

FAQs

1. What is the primary innovation protected by Patent 7,320,999?
It covers a novel chemical compound with specific structural features, along with its methods of synthesis and use in treating certain conditions.

2. How broad are the claims of this patent?
The claims are specific to the described compound’s structure, its synthesis process, and its therapeutic uses—covering an invention with moderate scope, leaving room for similar but distinct compounds.

3. Are there similar patents in other jurisdictions?
Yes, patent families with equivalents in Europe, Japan, and other markets exist, protecting similar compounds and applications.

4. What is the potential impact of patent expiration?
Expiration in April 2022 allows generic competitors to enter the market unless new patents or data exclusivities are obtained.

5. How does this patent influence the development of related drugs?
It shapes the R&D landscape, with competitors needing to navigate around its claims or seek licensing if they develop similar compounds.


References
[1] United States Patent and Trademark Office. Patent 7,320,999.
[2] World Intellectual Property Organization. Patent scope and family data.
[3] WIPO PATENTSCOPE. Patent citation and legal status data.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,320,999

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,320,999

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 53 487Nov 19, 1998

International Family Members for US Patent 7,320,999

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1131065 ⤷  Start Trial C300675 Netherlands ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial CA 2014 00036 Denmark ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial PA2014023 Lithuania ⤷  Start Trial
European Patent Office 1131065 ⤷  Start Trial 92488 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.